MPs have expressed concern that nearly half of clinical trials in the UK fail to publish their results, “presenting risks to human health and increasing research wastage”.
News
AZ sheds Nexium, Vimovo rights to Gruenenthal
AstraZeneca is continuing to shed products outside the scope of its three core therapy areas with the sale of certain rights to Nexium and Vimovo to Grünenthal.
Janssen unveils long-term data for HIV drug Symtuza
Janssen has unveiled new late-stage data on Symtuza showing positive long-term efficacy and safety in antiretroviral treatment-naïve adults with HIV.
Digital GP provider launches in the UK
Digital GP provider LIVI has now launched in the UK through a new partnership with the NHS and a paid for on-demand service.
NICE rejects Genzyme’s Caprelsa for medullary thyroid cancer
NICE has published draft guidelines rejecting Sanofi Genzyme’s Caprelsa for treating medullary thyroid cancer (MTC) that cannot be operated on or has spread around the body.
Encouraging data for ViiV’s long-acting, two-drug HIV therapy
ViiV Healthcare has unveiled encouraging mid-stage data backing a long-acting formulation of its two-drug regimen cabotegravir and rilpivirine for the treatment of HIV.
Lukewarm response to chancellor’s Budget
Chancellor Philip Hammond has confirmed the planned funding boost for the NHS and announced an additional emergency cash injection for social services in his Autumn budget, but critics argue it will not be enough to weather the storm of increasing demand, inefficient service delivery and a workforce crisis.
Diabetes causing 500 premature deaths a week
A new analysis by Diabetes UK has calculated that 500 people with diabetes die prematurely every week in England and Wales, with a significant number of these deaths down to avoidable complications.
Half of all kidney cancer patients initially misdiagnosed
Half of all patients with kidney cancer are initially misdiagnosed, data from Kidney Cancer UK’s patient survey has revealed.
Novartis and Pfizer link to develop NASH combo therapy
Novartis and Pfizer have announced an agreement that aims to advance the treatment of non-alcoholic steatohepatitis (NASH), a form of liver disease.
AbbVie’s Venclyxto hit with NICE rejection
Draft guidelines do not recommend NHS use of AbbVie’s Venclyxto for treating relapsed or refractory chronic lymphocytic leukaemia (CLL).
US approves first-in-class flu drug
The US Food and Drug Administration has approved Roche/Shionogi & Co’s Xofluza for the treatment of acute uncomplicated flu, opening the door to the first new antiviral with a novel mechanism of action in nearly 20 years.
NICE turns down hyperkalaemia therapies
Preliminary guidelines released by the National Institute for Health and Care Excellence do not recommend NHS funding for hyperkalaemia treatments Lokelma and Veltassa.
Health driving London’s digital lead in Europe
London leads this increasingly important study by a huge margin, finds new study
Gilead raises outlook despite dip in revenue
Total revenues were $5.6 billion in 2018 compared to $6.5 billion in 2017
